Author | Rachel Narozniak, MA | OncLive

Author | Rachel Narozniak, MA


Immuno-oncology Agents Face Off in NSCLC

August 10, 2020


Investigators will pit 2 PD-1/PD-L1–pathway agents against each other in a bid to determine which therapy can confer the greatest survival benefit in patients with PD-L1–high, advanced non–small cell lung cancer.

Immune Checkpoint Inhibitor Therapy Is Linked to COVID-19 Severity

August 10, 2020


Immunotherapy use is associated with a higher risk for hospitalization and severe coronavirus disease 2019 infection in patients with cancer and the novel respiratory virus.

Ripretinib Approval Advances Recurrent GIST Paradigm

August 03, 2020


Ripretinib has become the first therapy specifically approved for the fourth-line treatment of gastrointestinal stromal tumors, a clinical setting with an unmet medical need because of the poor prognosis of patients with progressive disease.

New Focus Needed on Preventing Brain Metastases in Early Breast Cancer

August 01, 2020


Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.